Related Experiment Video
Updated: May 20, 2025
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells
Ralf Weiskirchen1, Sabine Weiskirchen1, Chiara Grassi2
1Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany.
Introduction:
Hepatocellularcarcinoma (HCC), the primary form of liver cancer, is the second leading cause of cancer-related deaths worldwide. Current therapies have limited effectiveness, particularly in advanced stages of the disease, highlighting the need for innovative treatment options. Small-interfering RNA(siRNA) molecules show great promise as a therapeutic solution since they can inhibit the expression of genes promoting HCC growth. Their cost-effective synthesis has further encouraged their potential use as novel drugs. However, siRNAs are vulnerable to degradation in biological environments, necessitating protective delivery systems. Additionally, targeted delivery to HCC is critical for optimal efficacy and minimal undesired side effects.
Areacovered:
This review addresses the challenges associated with the delivery of siRNA toHCC, discussing and focusing on delivery systems based on lipid and polymeric nanoparticles in publications from the past five years.
Expert Opinion:
Future nano particles will need to effectively cross the vessel wall, migrate through the extracellular matrix and finally cross the HCC cell membrane. This may be achieved by optimizing nanoparticle size, the equipment of nanoparticles withHCC targeting moieties and loading nanoparticles with siRNAs againstHCC-specific oncogenes.
Insights
Hepatocellular carcinoma (HCC) demands new treatments. Lipid and polymeric nanoparticles offer promising delivery for small-interfering RNA (siRNA) to combat liver cancer, but require further optimization for cellular targeting and penetration.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
- Existing therapies for HCC, especially advanced stages, show limited efficacy.
- Small-interfering RNA (siRNA) presents a promising therapeutic strategy for HCC by inhibiting oncogenic gene expression.
Purpose of the Study:
- To review recent advancements in siRNA delivery systems for HCC.
- To focus on lipid and polymeric nanoparticles for targeted HCC therapy.
- To identify challenges and future directions in nanoparticle-based siRNA delivery for liver cancer.
Main Methods:
- Comprehensive literature review of studies published in the last five years.
- Analysis of lipid and polymeric nanoparticle formulations for siRNA delivery.
- Evaluation of targeting strategies and delivery mechanisms for HCC.
Main Results:
- Nanoparticle-based delivery systems are crucial for protecting siRNA from degradation and enabling targeted delivery to HCC.
- Lipid and polymeric nanoparticles show potential for effective siRNA delivery, but challenges remain.
- Optimization of nanoparticle characteristics is key for enhanced therapeutic outcomes.
Conclusions:
- Targeted delivery of siRNA using advanced nanoparticle systems is essential for effective HCC treatment.
- Future research should focus on optimizing nanoparticles for improved tumor penetration and cellular uptake.
- Nanoparticle engineering, including size optimization and surface functionalization with targeting ligands, is critical for advancing siRNA-based HCC therapies.
More Related Videos
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
09:09Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi